Financial toxicity in gynecologic oncology.

ABSTRACT: OBJECTIVES:Financial toxicity is increasingly recognized as an adverse outcome of cancer treatment. Our objective was to measure financial toxicity among gynecologic oncology patients and its association with demographic and disease-related characteristics; self-reported overall health; and cost-coping strategies. METHODS:Follow-up patients at a gynecologic oncology practice completed a survey including the COmprehensive Score for Financial Toxicity (COST) tool and a self-reported overall health assessment, the EQ-VAS. We abstracted disease and treatment characteristics from medical records. We dichotomized COST scores into low and high financial toxicity and assessed the correlation (r) between COST scores and self-reported health. We calculated risk ratios (RR) and 95% confidence intervals (CI) for the associations of demographic and disease-related characteristics with high financial toxicity, as well as the associations between high financial toxicity and cost-coping strategies. RESULTS:Among 240 respondents, median COST score was 29. Greater financial toxicity was correlated with worse self-reported health (r?=?0.47; p?

SUBMITTER: Bouberhan S 

PROVIDER: S-EPMC7001853 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature